Literature DB >> 10394483

Transcranial magnetic stimulation of left temporoparietal cortex in three patients reporting hallucinated "voices".

R E Hoffman1, N N Boutros, R M Berman, E Roessler, A Belger, J H Krystal, D S Charney.   

Abstract

BACKGROUND: Prior studies suggest that auditory hallucinations of "voices" arise from activation of speech perception areas of the cerebral cortex. Low frequency transcranial magnetic stimulation (TMS) can reduce cortical activation.
METHODS: We have studied three schizophrenic patients reporting persistent auditory hallucinations to determine if low frequency TMS could curtail these experiences. One hertz stimulation of left temporoparietal cortex was compared with sham stimulation using a double-blind, cross-over design.
RESULTS: All three patients demonstrated greater improvement in hallucination severity following active stimulation compared to sham stimulation. Two of the three patients reported near total cessation of hallucinations for > or = 2 weeks.
CONCLUSIONS: TMS may advance our understanding of the mechanism and treatment of auditory hallucinations.

Entities:  

Mesh:

Year:  1999        PMID: 10394483     DOI: 10.1016/s0006-3223(98)00358-8

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  48 in total

1.  Neuromodulation and Transcranial Mag Netic Stimulation (TMS): A 21st Century Paradigm for Therapeutics in Psychiatry.

Authors:  John P O'Reardon; Andrew D Peshek; Rocio Romero; Pilar Cristancho
Journal:  Psychiatry (Edgmont)       Date:  2006-01

2.  Repetitive transcranial magnetic stimulation over temporoparietal cortices in the treatment of refractory auditory hallucinations in patients with schizophrenia.

Authors:  Joachim Hallmayer
Journal:  Curr Psychiatry Rep       Date:  2005-06       Impact factor: 5.285

3.  Neuromodulation Treatments for Schizophrenia.

Authors:  Mehmet E Dokucu
Journal:  Curr Treat Options Psychiatry       Date:  2015-07-03

4.  Repetitive TMS combined with exposure therapy for PTSD: a preliminary study.

Authors:  Elizabeth A Osuch; Brenda E Benson; David A Luckenbaugh; Marilla Geraci; Robert M Post; Una McCann
Journal:  J Anxiety Disord       Date:  2008-03-28

5.  Altered Global Signal Topography in Schizophrenia.

Authors:  Genevieve J Yang; John D Murray; Matthew Glasser; Godfrey D Pearlson; John H Krystal; Charlie Schleifer; Grega Repovs; Alan Anticevic
Journal:  Cereb Cortex       Date:  2017-11-01       Impact factor: 5.357

Review 6.  The treatment of hallucinations in schizophrenia spectrum disorders.

Authors:  Iris E C Sommer; Christina W Slotema; Zafiris J Daskalakis; Eske M Derks; Jan Dirk Blom; Mark van der Gaag
Journal:  Schizophr Bull       Date:  2012-02-24       Impact factor: 9.306

Review 7.  Transcranial magnetic stimulation: a neuroscientific probe of cortical function in schizophrenia.

Authors:  Shawn M McClintock; Catarina Freitas; Lindsay Oberman; Sarah H Lisanby; Alvaro Pascual-Leone
Journal:  Biol Psychiatry       Date:  2011-05-14       Impact factor: 13.382

8.  Treatment of auditory verbal hallucinations with transcranial magnetic stimulation in a patient with psychotic major depression: one-year follow-up.

Authors:  Catarina Freitas; Chester Pearlman; Alvaro Pascual-Leone
Journal:  Neurocase       Date:  2011-06-28       Impact factor: 0.881

9.  Treatment of auditory hallucinations with bilateral theta burst stimulation (cTBS): protocol of a randomized, double-blind, placebo-controlled, multicenter trial.

Authors:  Christian Plewnia; Bettina Brendel; Tobias Schwippel; Peter Martus; Joachim Cordes; Alkomiet Hasan; Andreas J Fallgatter
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-12-09       Impact factor: 5.270

10.  Theta Burst Transcranial Magnetic Stimulation for Auditory Verbal Hallucinations: Negative Findings From a Double-Blind-Randomized Trial.

Authors:  Sanne Koops; Edwin van Dellen; Maya J L Schutte; Wendy Nieuwdorp; Sebastiaan F W Neggers; Iris E C Sommer
Journal:  Schizophr Bull       Date:  2015-07-28       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.